Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference
November 12 2019 - 7:30AM
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
immunotherapy company, today announced that company management will
make a corporate presentation and host 1x1 meetings at the 10th
Annual Jefferies 2019 London Healthcare Conference, being held in
London on November 20 & 21. The presentation is scheduled for
November 20 2019 at 8:00am local time.
ALLOCETRATM by Enlivex was designed to provide a novel
immunotherapy mechanism of action that targets
life-threatening clinical indications that are defined as “unmet
medical needs”, including prevention or treatment of
complications associated with bone marrow transplantations (BMT)
and/or hematopoietic stem cell transplantations (HSCT); organ
dysfunction and acute multiple organ failure associated with
sepsis; and enablement of an effective treatment of solid tumors
via immune checkpoint rebalancing.
Enlivex announced on November 4, 2019 positive interim safety
and efficacy data from an ongoing trial of off-the-shelf universal
Allocetra in patients with severe sepsis. The interim analysis
comparing Allocetra-treated patients with 37 severe sepsis patients
with equivalent source of infection and disease severity who were
hospitalized at the same hospital, demonstrated the potential of
Allocetra as therapy for prevention of sepsis-associated organ
failure and mortality.
For more information about the 10th Annual Jefferies 2019 London
Healthcare Conference, visit http://
https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/112019.
ABOUT ENLIVEXEnlivex is a clinical stage
immunotherapy company, developing an allogeneic drug pipeline for
immune system rebalancing. Immune system rebalancing is critical
for the treatment of life-threatening immune and inflammatory
conditions which involve an out of control immune system (e.g.
Cytokine Release Syndrome) and for which there are no approved
treatments (unmet medical needs), as well as solid tumors
immune-checkpoint rebalancing. For more information, visit
http://www.enlivex.com.
ENLIVEX CONTACT:Shachar Shlosberger, CFOEnlivex
Therapeutics, Ltd.shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024